Shigeatsu Tanimukai
Kyoto Prefectural University of Medicine
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Shigeatsu Tanimukai.
Leukemia | 1997
Yoshikazu Ohmizono; Hideaki Sakabe; Takafumi Kimura; Shigeatsu Tanimukai; T Matsumura; H Miyazaki; Sd Lyman; Yoshiaki Sonoda
We studied the effects of stem cell factor (SCF) and flt3 ligand (FL) on the ex vivo expansion of human umbilical cord blood (CB)-derived CD34+ cells in combination with various cytokines, including interleukin (IL)-3, IL-6, IL-11, and c-Mpl ligand (thrombopoietin, TPO), in a short-term serum-free liquid suspension culture system. Among the two-factor combinations tested, SCF plus IL-3 most effectively expanded committed progenitor cells, including mixed colony-forming units (CFU-Mix). The expansion efficiency (EE) of FL for each progenitor was inferior to that of SCF in the presence of various cytokines, except TPO. IL-6 significantly increased the EE for granulocyte/macrophage colony-forming units (CFU-GM) obtained with SCF + IL-3 or FL + IL-3. Interestingly, TPO markedly augmented the EE for committed progenitors, including CFU-GM, erythroid burst-forming units (BFU-E), and CFU-Mix, in the presence of SCF + IL-3 or FL + IL-3. The combinations of SCF + IL-3 + TPO + IL-6 or IL-11 maximally stimulated the expansion of committed progenitors. The maximum EE for CFU-GM, BFU-E, and CFU-Mix was respectively 197-fold (day 14), 60-fold (day 7) and 51-fold (day 14). Other combinations of cytokines without IL-3 failed to expand effectively these committed progenitors. Our data demonstrate that it is possible to expand human CB-derived committed progenitors in vitro using SCF or FL with several other cytokines including TPO, and that IL-3 is the key cytokine promoting the expansion of human hematopoietic progenitors in the presence of SCF or FL.
Stem Cells | 1997
Hideaki Sakabe; Yoshikazu Ohmizono; Shigeatsu Tanimukai; Takafumi Kimura; Kazuhiro J. Mori; Tatsuo Abe; Yoshiaki Sonoda
We have investigated the functional characteristics of peripheral blood‐derived CD34+ cells mobilized by a combination of chemotherapy and G‐CSF (mobilized peripheral blood‐derived [MPB] CD34+ cells). In this study, subpopulations of MPB CD34+ cells have been directly compared in clonal cultures, long‐term cultures with bone marrow (BM) stromal cells, and single‐cell cultures. MPB CD34+ cells could be subdivided by expression levels of HLA‐DR (DR), CD38, CD33 and c‐kit antigens. The majority of MPB CD34+ cells expressed DR and CD38 antigens. In contrast, approximately 60% and 20% of the MPB CD34+ cells expressed CD33 and c‐kit antigens, respectively. Interestingly, MPB CD34+ cells can be subdivided into three fractions which express high, low or negative levels of c‐kit receptor. All types of committed progenitors were observed in populations of CD34+DR+, CD34+DR−, CD34+CD33−, CD34+CD38+ and CD34+ c‐kitlow cells. Colony forming unit‐granulocyte/macrophage was highly enriched in the population of CD34+CD33+ cells, whereas BFU‐E was highly enriched in the population of CD34+ c‐kithigh cells. In the population of CD34+CD38− cells, however, a few myeloid progenitors were detected. In addition, limiting dilution analyses clearly showed that the long‐term culture‐initiating cell (LTC‐IC) is enriched in the populations of CD34+DR−, CD34+CD33− and CD34+c‐kit− or low cells, but very few in CD34+ c‐kithigh cells, and that CD38 antigen is not a useful marker for the enrichment of LTC‐IC derived from MPB CD34+ cells. Moreover, single cell clone sorting experiments clearly demonstrated the functional differences between CD34+CD38+ and CD34+CD38− cells as well as CD34+ cells expressing different levels of c‐kit receptor. Our results suggest that an immunophenotype of LTC‐IC is different between BM‐, cord blood‐ and MPB‐derived CD34+ cells and that primitive and committed progenitors existing in these sources may be functionally different.
European Journal of Haematology | 2009
Yoshiaki Sonoda; Takafumi Kimura; Hideaki Sakabe; Shigeatsu Tanimukai; Yoshikazu Ohmizono; Shuichi Nakagawa; Shouhei Yokota; Stewart D. Lyman; Tatsuo Abe
Abstract: We studied the effect of human flt3/flk2 ligand (FL) on the proliferation and differentiation of purified CD34+ blood progenitors which express different levels of c‐kit protein in clonal cell culture in comparison with that of stem cell factor (SCF). FL alone did not support significant colony formation. However, FL significantly enhanced neutrophil colony (CFU–G) formation in the presence of granulocyte‐colony stimulating factor (G–CSF) by peripheral blood (PB)‐derived CD34+c‐kit− cells which contained a large number of CFU–G. In addition, FL could synergistically increase the number of CFU–G supported by a combination of interleukin (IL)‐3 and G–CSF, as did SCF. As we reported previously, SCF showed a significant burst‐promoting activity (BPA). In contrast, FL did not exhibit any BPA on PB‐derived CD34+c‐kithigh cells in which erythroid‐burst (BFU‐E) was highly enriched. However, FL could synergize with IL‐3 or GM–CSF in support of erythrocyte‐containing mixed (E‐Mix) colony by PB‐derived CD34+c‐kithigh or low cells in the presence of Epo. Replating of E‐Mix colonies derived from CD34+c‐kithigh cells supported by IL‐3+Epo+SCF yielded more secondary colonies than those supported by IL‐3+Epo or IL‐3+Epo+FL. When PB‐derived CD34+c‐kitlow cells which represent a more immature population than CD34+c‐kithigh cells were used as the target, number of secondary colonies supported by IL‐3+Epo, IL‐3+Epo+SCF or IL‐3+Epo+FL was comparable. However, the number of lineages expressed in the secondary culture was significantly larger in the primary culture containing IL‐3+Epo+FL than in that containing IL‐3+Epo. These results suggest that FL not only acts on neutrophilic progenitors, but also on more immature multipotential progenitors.
British Journal of Haematology | 1997
Yoshiaki Sonoda; Takafumi Kimura; Yoshikazu Ohmizono; Hideaki Sakabe; Shigeatsu Tanimukai; Shouhei Yokota; Steven C. Clark; Tatsuo Abe
We studied the interaction of interleukin (IL)‐4 and other burst‐promoting activity (BPA) factors, such as IL‐3, granulocyte/macrophage colony‐stimulating factor (GM‐CSF), IL‐9 and stem cell factor (SCF), on erythroid burst‐forming unit (BFU‐E) and erythrocyte‐containing mixed (CFU‐Mix) colony formation in serum‐free culture. IL‐4 alone did not support mixed colony formation in the presence of erythropoietin (Epo). However, IL‐4 showed weak but significant BPA when peripheral blood (PB)‐derived CD34+c‐kitlow cells were used as the target population. The BPA of IL‐4 was much weaker than that of IL‐3, which exerted the most potent activity, as previously reported. When CD34+c‐kithigh cells were used as the target, four factors known to have BPA, IL‐3, GM‐CSF, IL‐9 and SCF, could express BPA. In contrast, IL‐4 alone failed to support erythroid burst formation. Interestingly, IL‐4 showed a remarkable enhancing effect with SCF in promoting the development of erythroid burst and erythrocyte‐containing mixed colonies from CD34+c‐kitlow and CD34+c‐kithigh cells. Delayed addition of SCF + Epo or IL‐4+Epo to the cultures initiated with either IL‐4 or SCF alone clearly demonstrated that SCF was a survival factor for both BFU‐E and CFU‐Mix progenitors. In contrast, the survival effect of IL‐4 was much weaker than that of SCF, and appeared to be more important for progenitors derived from CD34+c‐kitlow cells than for those derived from CD34+c‐kithigh cells. It was recently reported that CD34+c‐kitlow cells represent a more primitive population than CD34+c‐kithigh cells. Taken together, these results suggest that IL‐4 helps to recruit primitive progenitor cells in the presence of SCF.
Blood | 1997
Takafumi Kimura; Hideaki Sakabe; Shigeatsu Tanimukai; Tatsuo Abe; Yoji Urata; Kiyoshi Yasukawa; Akira Okano; Tetsuya Taga; Haruo Sugiyama; Tadamitsu Kishimoto; Yoshiaki Sonoda
Experimental Hematology | 1997
Shigeatsu Tanimukai; Takafumi Kimura; Hideaki Sakabe; Yoshikazu Ohmizono; T. Kato; H. Miyazaki; Hisakazu Yamagishi; Yoshiaki Sonoda
Blood | 1994
Yoshiaki Sonoda; Hideaki Sakabe; Y Ohmisono; Shigeatsu Tanimukai; Shouhei Yokota; S Nakagawa; Sc Clark; Tatsuo Abe
Jpn J Gastroenterol Surg, Nihon Shokaki Geka Gakkai zasshi | 1990
Hisashi Amaike; Kiyokazu Akioka; Hiromitsu Fujino; Shigeatsu Tanimukai; Hiroyuki Ameno; Tatsuyuki Ann; Tomoji Nishimoto; Eito Ikeda; Fumitaka Muto; Hideaki Kurioka; Kyouzou Hashimoto; Takao Oouchi; Kanichi Tanaka; Yoshihiro Harada; Genkou Ishimine
Archive | 2010
Akira Okano; Tetsuya Taga; Haruo Sugiyama; Tadamitsu Kishimoto; Yoshiaki Sonoda; Takafumi Kimura; Hideaki Sakabe; Shigeatsu Tanimukai; Tatsuo Abe; Yoji Urata; Kiyoshi Yasukawa
日本アフェレシス学会雑誌 | 1997
Yoshiaki Sonoda; Hideaki Sakabe; Takafumi Kimura; Shigeatsu Tanimukai; Yoshikazu Ohmizono; Kazuhiro J. Mori; Tatsuo Abe